卡瑞利珠单抗联合化疗对晚期非小细胞肺癌患者肿瘤标志物及生存情况的影响

打开文本图片集

Influence of Camrelizumab Combined with Chemotherapy on Tumor Markers and Survival Status in Patients with Advanced Non-small CellLung Cancer/WANGLei，YANG Qin，CHENG Xiaobo，YANG Li， LI Qian.//Medical Innovation of China，2025，22（17）： 035-038

[Abstract]Objective： To analyze the influence of Camrelizumab combined with chemotherapy on patients with advanced non-small cellung cancer （NSCLC）.Method： The clinical data of 82 patients with advanced NSCLC admited to angyang People's Hospital fromFebruary 2O20 to February 2O23 were reviewed.They were divided into two groups according to diferent treatment methods， with 41 cases in each group. The control group received chemotherapy，while the observation group was treated with Camrelizumab inaddition to the control group. The therapeutic effects of the two groups were compared.Result： The total effective rate and survival rate of the observation group were both higher than those of the control group （ P <0.05）.Moreover，after the treatment，the levels of various tumor markers and C8 + in the observation group were lower than those in the control group，and C 3+ C4 ↓+ and the scores ofeach dimension inthe World Health Organization quality of life mini-scale were higher than thosein thecontrol group，the differenceswere statisticallysignificant（ P <0.05）.Therewasno statisticallysignificant difference in the incidence of adverse reactions between the two groups （P>O.O5）. Conclusion： Camrelizumab combinedwith chemotherapycan inhibit the proliferationofcancercells in patients with advanced NSCLC，improve immune function，enhance the quality of life and survival rate，and has no serious adverse reactions.

[Key Words]Advanced non-small cellung cancerCamrelizumabQuality of lifeSurvival rate

First-author's address： epartment of Oncology，angyang People's Hospital， angyang 444100.China

doi：10.3969/j.issn.1674-4985.2025.17.008

非小细胞肺癌（NSCLC）为肺癌的常见类型，是临床高发的恶性肿瘤[1-2]。（剩余5294字）